Behringer, Karolin ; Goergen, Helen ; Hitz, Felicitas ; Zijlstra, Josée M ; Greil, Richard 
; Markova, Jana ; Sasse, Stephanie ; Fuchs, Michael ; Topp, Max S ; Soekler, Martin ; Mathas, Stephan ; Meissner, Julia ; Wilhelm, Martin ; Koch, Peter ; Lindemann, Hans-Walter ; Schalk, Enrico ; Semrau, Robert ; Kriz, Jan ; Vieler, Tom ; Bentz, Martin ; Lange, Elisabeth ; Mahlberg, Rolf ; Hassler, Andre ; Vogelhuber, Martin ; Hahn, Dennis ; Mezger, Jörg ; Krause, Stefan W ; Skoetz, Nicole ; Böll, Boris ; von Tresckow, Bastian ; Diehl, Volker ; Hallek, Michael ; Borchmann, Peter ; Stein, Harald ; Eich, Hans ; Engert, Andreas
; Markova, Jana ; Sasse, Stephanie ; Fuchs, Michael ; Topp, Max S ; Soekler, Martin ; Mathas, Stephan ; Meissner, Julia ; Wilhelm, Martin ; Koch, Peter ; Lindemann, Hans-Walter ; Schalk, Enrico ; Semrau, Robert ; Kriz, Jan ; Vieler, Tom ; Bentz, Martin ; Lange, Elisabeth ; Mahlberg, Rolf ; Hassler, Andre ; Vogelhuber, Martin ; Hahn, Dennis ; Mezger, Jörg ; Krause, Stefan W ; Skoetz, Nicole ; Böll, Boris ; von Tresckow, Bastian ; Diehl, Volker ; Hallek, Michael ; Borchmann, Peter ; Stein, Harald ; Eich, Hans ; Engert, Andreas Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
Behringer, Karolin, Goergen, Helen, Hitz, Felicitas, Zijlstra, Josée M, Greil, Richard, Markova, Jana, Sasse, Stephanie, Fuchs, Michael, Topp, Max S, Soekler, Martin, Mathas, Stephan, Meissner, Julia, Wilhelm, Martin, Koch, Peter, Lindemann, Hans-Walter, Schalk, Enrico, Semrau, Robert, Kriz, Jan, Vieler, Tom, Bentz, Martin, Lange, Elisabeth, Mahlberg, Rolf, Hassler, Andre, Vogelhuber, Martin, Hahn, Dennis, Mezger, Jörg, Krause, Stefan W , Skoetz, Nicole, Böll, Boris, von Tresckow, Bastian, Diehl, Volker, Hallek, Michael, Borchmann, Peter, Stein, Harald, Eich, Hans and Engert, Andreas
(2015)
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
The Lancet 385 (9976), pp. 1418-1427.
Date of publication of this fulltext: 19 Dec 2024 07:35
Article
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | The Lancet | ||||
| Publisher: | ELSEVIER SCIENCE INC | ||||
|---|---|---|---|---|---|
| Place of Publication: | NEW YORK | ||||
| Volume: | 385 | ||||
| Number of Issue or Book Chapter: | 9976 | ||||
| Page Range: | pp. 1418-1427 | ||||
| Date | 2015 | ||||
| Institutions | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) | ||||
| Identification Number |
| ||||
| Keywords | 2ND MALIGNANCY RISK; RADIATION-THERAPY; COMBINED-MODALITY; FIELD RADIOTHERAPY; CLINICAL-TRIALS; 2 CYCLES; DISEASE; CHEMOTHERAPY; VINBLASTINE; METAANALYSIS; | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 60505 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric